Tenaya Therapeutics Inc
Company Profile
Business description
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
Contact
171 Oyster Point Boulevard
Suite 500, 5th Floor
South San FranciscoCA94080
USAT: +1 650 825-6990
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
70
Stocks News & Analysis
stocks
Wide moat share remains cheap despite rising costs
stocks
Fair value upgrade for ASX listed fast food chain
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,374.90 | 50.40 | 0.54% |
| CAC 40 | 8,439.20 | 13.81 | -0.16% |
| DAX 40 | 26,266.14 | 159.54 | 0.61% |
| Dow JONES (US) | 53,566.29 | 149.13 | 0.28% |
| FTSE 100 | 10,886.16 | 31.84 | 0.29% |
| HKSE | 25,511.10 | 6.23 | -0.02% |
| NASDAQ | 26,099.55 | 119.36 | 0.46% |
| Nikkei 225 | 65,856.43 | 328.34 | 0.50% |
| NZX 50 Index | 13,992.72 | 110.84 | 0.80% |
| S&P 500 | 7,670.12 | 17.26 | 0.23% |
| S&P/ASX 200 | 9,164.60 | 54.30 | 0.60% |
| SSE Composite Index | 3,889.44 | 7.44 | 0.19% |